Pilot randomised controlled trial evaluating feasibility,safety and adherence to psyllium husk in peritoneal dialysis: The FIBRE-PD trial

Abstract

Background

Patients receiving peritoneal dialysis (PD) often report problems with constipation. Constipation in PD is associated with increased risks of mechanical and infectious complications, such as poor drainage and fluid removal, catheter migration and peritonitis. A natural fibre supplement, psyllium husk, has been identified as a potential alternative therapy to minimise the risk of constipation for patients receiving PD.

Methods

FIBRE-PD is a prospective parallel-arm open-label feasibility study in which patients on PD were 1:1 randomly assigned to receive either psyllium husk (intervention group) or continue routine Movicol^® (control group) for four weeks (28 days). The primary outcome was feasibility, defined as successful recruitment of 60 patients, representing 70% of eligible PD patients. Secondary outcomes included adherence, retention, safety, bowel frequency and patient-reported outcomes (e.g., gastrointestinal symptom burden, quality of life).

Results

Overall, 96 patients were screened for eligibility. Sixty-six (69%) were deemed not eligible, mainly due to non-adherence to prescribed regular Movicol (n = 41, 62%). Among 30 eligible patients, 20 patients (67% of eligible population) were successfully recruited into the study. The intervention group demonstrated high retention (77%), adherence rates (78%) and significant improvement in gastrointestinal symptoms and quality of life compared to patients in the control group. No adverse outcomes were reported.

Conclusion

The FIBRE-PD did not meet its original recruitment target due to an unexpectedly high number of ineligible patients. The recruited proportion almost reached the pre-specified target of 70% of eligible patients, and participants in the intervention group demonstrated high retention and adherence rates with observed benefits in gastrointestinal symptom burden and quality of life.

Graphical abstract

This is a visual representation of the abstract.

Keywords

Constipation fibre outcome peritoneal dialysis psyllium

Get full access to this article

View all access options for this article.

References

ANZDATA. 43rd Annual Report 2020 (Data to 2019) – anzdata.org.au.

Kosmadakis

Albaret

Da Costa Correia

, et al. Constipation in peritoneal dialysis patients. Perit Dial Int 2019; 39: 399–404.

C-Y

Pei

X-H

, et al. Gastrointestinal symptoms predict peritonitis rates in CAPD patients. Clin Nephrol 2012; 77: 267–274.

Sumida

Yamagata

Kovesdy

. Constipation in CKD. Kidney Int Rep 2020; 5: 121–134.

Manera

Johnson

Craig

, et al.

Patient and caregiver priorities for outcomes in peritoneal dialysis: multinational nominal group technique study.

Clin J Am Soc Nephrol 2019; 14: 74–83.

Sutton

Ovington

Engel

. A multi-centre, randomised trial to assess whether increased dietary fibre intake (using a fibre supplement or high-fibre foods) produces healthy bowel performance and reduces laxative requirement in free living patients on peritoneal dialysis. J Ren Care 2014; 40: 157–163.

McRorie

JW Jr

Fahey

GC Jr

Gibb

, et al. Laxative effects of wheat bran and psyllium: resolving enduring misconceptions about fiber in treatment guidelines for chronic idiopathic constipation. J Am Assoc Nurse Pract 2020; 32: 15–23.

Noureddin

Mohsen

Payman

. Effects of psyllium vs. placebo on constipation, weight, glycemia, and lipids: a randomized trial in patients with type 2 diabetes and chronic constipation. Complement Ther Med 2018; 40: 1–7.

Lai

, et al. Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial. Gut Microbes 2023; 15: 2197837.

10.

Garg

. Inflammation in irritable bowel syndrome (IBS): role of psyllium fiber supplementation in decreasing inflammation and physiological management of IBS. Turk J Gastroenterol 2021; 32: 108–110.

11.

Savino

Viola

Maiullari

, et al. Efficacy and tolerability of peg-only laxative on faecal impaction and chronic constipation in children: a controlled double blind randomized study vs a standard peg-electrolyte laxative. BMC Pediatr 2012; 12: 78.

12.

Hayat

Johnson

Manera

, et al. Experiences and perspectives of patients and their caregivers on gastrointestinal symptoms in peritoneal dialysis: workshop report. Perit Dial Int 2025; Advance Online Publication. DOI: 10.1177/08968608251361298.

13.

See

Johnson

Hawley

, et al. Risk predictors and causes of technique failure within the first year of peritoneal dialysis: an Australia and New Zealand dialysis and transplant registry (ANZDATA) study. Am J Kidney Dis 2018; 72: 188–197.

14.

Hayat

Walker

Viecelli

, et al. Range and consistency of gastrointestinal outcomes reported in peritoneal dialysis trials: a systematic review. Perit Dial Int 2023; 43: 315–323.

15.

Mehrotra R, Davison SN, Farrington K, et al. Managing the symptom burden associated with maintenance dialysis: conclusions from a kidney disease: improving global outcomes (KDIGO). Controvers Conf. Kidney Int 2023; 104: 441–454.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.02 MB

0.00 MB